Loading
Life sciences · Journal article
Scientific Reports · September 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Herein, a bio-metal–organic framework (BioMOF) was synthesized using the bisphosphonate drug alendronate (ALD) as both the organic linker and therapeutic agent, coordinated with Mg²⁺ ions to form Mg–ALD. To enable active targeting, the framework was functionalized with folic acid (FA), yielding Mg–ALD/FA. The structural and morphological properties of the BioMOFs were characterized using scanning and transmission electron microscopy (SEM/TEM), X-ray diffraction (XRD), energy-dispersive X-ray spectroscopy (EDX), Fourier-transform infrared spectroscopy (FTIR), and ultraviolet-visible (UV–Vis) spectroscopy. Drug release investigations revealed a pronounced pH-responsive behavior, with significantly enhanced ALD release under acidic conditions (pH 5.5) compared to physiological pH (7.4). Kinetic analysis suggested that the release process is predominantly diffusion-controlled under physiological conditions, while weakening of Mg–ALD coordination under acidic environments. In vitro cytotoxicity studies (MTT assay) on NIH/3T3, HeLa, and LnCap cell lines demonstrated selective toxicity of Mg–ALD/FA toward folate receptor–positive HeLa cells, while minimal effects were observed on normal and FA-negative cells. After 72 h of treatment with 50 µg mL⁻¹ Mg–ALD/FA, HeLa cell viability decreased to approximately 25%. These findings demonstrate that Mg–ALD/FA represents a dual-function BioMOF in which alendronate serves simultaneously as a structural linker and therapeutic agent, offering controlled pH-responsive release and effective receptor-mediated targeting for cancer therapy.